Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
about
Rome Consensus Conference - statement; human papilloma virus diseases in malesEstimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccinationProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerCost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVSafety and Efficacy Data on Vaccines and Immunization to Human PapillomavirusAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialOral sex and oropharyngeal cancer: The role of the primary care physicians.Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort studySustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.Epidemiology and costs of cervical cancer screening and cervical dysplasia in ItalyIdentification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implicationsA population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialCancer prevention research - then and nowPrevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural UgandaDistribution of genital wart human papillomavirus genotypes in China: a multi-center study.Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodiesEvaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with MenSocial values and scientific evidence: the case of the HPV vaccines.Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceTargeting inhibitory pathways in cancer immunotherapy.Integrating clinical, community, and policy perspectives on human papillomavirus vaccinationSex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical modelsPrevalence of human papillomavirus infection and genotype distribution among high-risk Korean women for prospecting the strategy of vaccine development.HPV catch-up vaccination of young women: a systematic review and meta-analysis.Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervixEffect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses.Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.Protecting our Khmer daughters: ghosts of the past, uncertain futures, and the human papillomavirus vaccine.
P2860
Q21257274-8D85A3D1-8E1C-43CF-A7BF-4E7917CDFD50Q21261267-D776E427-1C86-44FC-B2BD-F672EF11D5BFQ24202048-B002FD27-DDC0-4911-B9E3-4756D7851374Q24235373-F73EB8D0-B8AA-441A-BD9B-0A74367389EFQ24607403-324D7CC5-0E2C-4D9B-908B-8D7286DF6BDBQ24655328-4638805F-8EC8-4905-AFFD-4EDFC81F6791Q26749285-D174D123-8621-4FFD-B89E-3C800058B4E3Q26783973-B0E46174-39DE-415B-A230-DD3F802EEBCDQ26799574-4FDD3F23-AB1A-4731-B0E8-5AD0B0A60D3BQ26828840-934459F3-BFA2-4D7F-A086-9E1447214859Q28750269-0E88ABA8-05F3-4A69-84AC-BC56C9AA4A1AQ30248928-01167567-9EAE-42A6-A7EF-359C0DE17420Q30409053-CF20CCD3-08E0-4EC3-B8C2-02DD2F02B849Q30558756-BD172C18-8EC1-4D71-9BF9-D00DF64E49BEQ30980654-124AE19A-17BD-483A-92FF-622B4D5F0C00Q33292779-B309FDEB-A735-4A7A-A7A0-7B0BBF501E4AQ33412571-6CAA67EE-D67D-42A6-BC97-1E7A2A13BAA2Q33469751-9F175ECB-2751-40ED-A9D1-DF84130B018FQ33573346-79383A3B-5278-46C1-9FF9-7DC5B001B665Q33626255-B3F9C28A-09C6-43BD-AFEC-2EBE03503FFDQ33726196-B7D6E2CF-FF18-439E-8DFF-ED4C43D0BC2DQ33760807-3523E3D3-978A-4C8A-AB0D-3A54EC4B78CDQ33777098-DADC550F-A967-4E6C-9550-859C2685FA72Q33780651-4897D262-1346-4457-AFBC-2C7C228EDE84Q33814136-6D4D0525-6413-47C7-81CB-D5772A241726Q33890189-0E5876D9-E77B-4A99-877F-90297F3C4FC5Q33892348-C6CF51BE-BC95-4612-9FA1-7A787EFE970FQ33924580-C216A7EC-FD54-45F0-8537-A7670E8634A7Q33950640-A147F645-8509-4530-8A1B-248C8469B5BAQ34078572-0786FC46-EE90-4BAB-BDD4-0141D63FE9D0Q34113476-8D6D2739-D1A8-4F59-9181-3BE67B6D9D33Q34116988-6D76A201-B626-428A-9030-DC5895748211Q34157209-138C2C78-8015-430A-A77B-E6CAE117D251Q34181909-7CFA8DCE-AC1C-4495-9AB5-D4E5666BEDC1Q34187128-761A4362-AD08-488E-B461-2CB8236C68EDQ34210255-06F67CDE-D2DE-4417-B36C-61D88600DB3FQ34335370-EFA3E0CE-A30C-4A2D-8EFE-2ACD98FE7715Q34439784-18914574-80F3-4A21-8073-379495A09A78Q34549645-801E3D69-BF47-4223-87BA-C2EEECCAC41FQ34644634-3C65D7A6-D3BE-4400-A330-EE199B11A1B7
P2860
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effect of prophylactic human p ...... ur randomised clinical trials.
@en
type
label
Effect of prophylactic human p ...... ur randomised clinical trials.
@en
prefLabel
Effect of prophylactic human p ...... ur randomised clinical trials.
@en
P1433
P1476
Effect of prophylactic human p ...... ur randomised clinical trials.
@en
P2093
Future II Study Group
Kevin A Ault
P304
P356
10.1016/S0140-6736(07)60852-6
P407
P577
2007-06-01T00:00:00Z